Cybrexa Therapeutics, a New Haven, CT-based cancer therapeutics company, secured $6m in Series B funding.
An investment vehicle affiliated with HighCape Partners, Connecticut Innovations, and a group of private investors participated in the round.
The company intends to use the funds to complete the build-out of its facilities and continue the development its tumor-localizing DNA repair inhibitors, which they refer to as Tumor Specific Drugs (TSDs).
Founded by Per Hellsund, Kevin Didden and Kevin Rakin, Cybrexa is a biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment.
This approach leverages a novel tumor-localizing peptide technology developed by a research laboratory at Yale.
Additional members of the founding team include Ranjit Bindra, M.D., Ph.D., and Peter Glazer, M.D., Ph.D., from the Yale School of Medicine.